LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts.

Sorry, there's nothing here.
020040020162017
Citations per Year

300 Citations

Semantic Scholar estimates that this publication has 300 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Ramalingam2016LBA1_PROA, title={LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts.}, author={Sandeep Ramalingam and Joseph Yang and Chee Khoon Lee and Tomoko Kurata and D . W . Kim and Thomas John and Naoyuki Nogami and Yuichiro Ohe and Pasi Antero J{\"a}nne}, journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer}, year={2016}, volume={11 4 Suppl}, pages={S152} }